ClinicalTrials.gg
RecruitingNCT07730281Updated Oct 28, 2026

PRA-216 COPD Safety and Biomarker Study

A Phase 2 interventional study of PRA-216 and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Prana Therapies Inc. Recruiting at 5 sites in Australia. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Prana Therapies Inc · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 28, 2026Now RecruitingFirst site in Australia+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia — 15 open to participants now, 19 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Australia.

Planned enrollment
114th of 132
40 · median 441
Started
2026
with 3 others
Phase 2
27 of 140
2 open now
Primary completion
2027-06
later than 8 of 18 live
Registered
140th of 140
by date

Among the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia, this one is the 114th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 8 of the 18 other live ones, and was the 140th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Pulmonary Disease, Chronic Obstructive with a site in Australia, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).

Read the detailed description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of PRA-216, administered by SC injection in participants with moderate to severe COPD who are on standard of care treatment consisting of dual (ICS/LAMA or ICS/LABA) or triple inhaled maintenance therapy (ICS, LABA and LAMA).

The study will enroll approximately 40 participants at multiple study site and participants will be randomized 1:1 to receive either PRA-216 or placebo subcutaneous injections four times throughout the study period.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Inflammatory response
  • pharmacokinetics
  • pharmacodynamics
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-80
  • Willing and able to attend all study visits, comply with study requirements.
  • Able and willing to provide written
  • Documented diagnosis prior for at least 12 months prior to screening.
  • Currently receiving maintenance COPD medications at a stable dose for at least 3 months prior to visit 1

Exclusion criteria

Exclusion Criteria:

  • Evidence of pulmonary condition or disease other than
  • Any physical or psychological condition that prohibits study completion
  • Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent
  • History of severe allergic reactions or
  • Major surgery occurring within 8 weeks months prior to first dose of product.
  • Use of any marketed or investigational monoclonal or polyclonal antibody therapy within 4 months or 5 half-lives prior to visit 1.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Active PRA-216

    Participants with moderate to severe COPD will be randomized to receive PRA-216

    Drug: PRA-216

  • Placebo comparator
    Placebo

    Participants with moderate to severe COPD will be randomized to receive placebo

    Drug: Placebo

Interventions

  • DrugPRA-216

    biologic

  • DrugPlacebo

    matching placebo for PRA-216

06

What researchers measure

Primary outcomes

  1. Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of PRA-216 in patients with moderate to severe COPD

    Time frame: 40 weeks

Secondary outcomes

  1. The effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in COPD participants

    FeNO is a non-invasive biomarker of airway inflammation in COPD. A higher number indicates higher inflammation. A reduction in FeNO levels might indicate functional activity of PRA-216.

    Time frame: 40 weeks

  2. Pharmacokinetics of PRA-216: Tmax in patients with COPD

    Time of maximum observed concentration of PRA-216 in plasma

    Time frame: 40 weeks

  3. Pharmacokinetics of PRA-216: AUC in patients with COPD

    Area under the curve of PRA-216 in plasma

    Time frame: 40 weeks

  4. Pharmacokinetics of PRA-216: Cmax in patients with COPD

    Maximum concentration of PRA-216 in plasma.

    Time frame: 40 weeks

  5. Immunogenicity of PRA-216: ADA in patients with COPD

    Incidence of anti-drug antibody following PRA-216 administration

    Time frame: 40 weeks

07

Study locations

4 of 5 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 9 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
5 sites added — first site in Australia
Show 5 added (5 Australia)
  • Emeritus Research Sydney · Botany, Australia
  • Campbelltown Hospital · Campbelltown, Australia
  • University of the Sunshine Coast · Birtinya, Australia
  • Griffith University · Southport, Australia
  • Emeritus Research Camberwell · Camberwell, Australia
Oct 28, 2026
Start date
Aug 1, 2026→Aug 25, 2026 (actual)
Oct 28, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedCurrently receiving maintenance COPD medications at a stable dose for at least 23 months prior to visit 1
Exclusion criteria
  • EditedKnown history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism within 12 months prior to the first dose of study agent
  • RemovedReceipt of immunosuppressant therapies for asthma within 3 months of screening
Oct 28, 2026
Secondary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedPharmacokinetics of PRA-216: T1/2Tmax in patients with COPDTime frame: 40 weeks
  • DescriptionThe effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in COPD participants: how it is measured was reworded
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    5 sites added — first site in Australia
    Show 5 added (5 Australia)
    • Emeritus Research Sydney · Botany, Australia
    • Campbelltown Hospital · Campbelltown, Australia
    • University of the Sunshine Coast · Birtinya, Australia
    • Griffith University · Southport, Australia
    • Emeritus Research Camberwell · Camberwell, Australia
    Start date Aug 1, 2026→Aug 25, 2026 (now actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedCurrently receiving maintenance COPD medications at a stable dose for at least 23 months prior to visit 1
    Exclusion criteria
    • EditedKnown history of illicit drug use or drug abuse, harmful alcohol use (at the Investigator's discretion), alcoholism within 12 months prior to the first dose of study agent
    • RemovedReceipt of immunosuppressant therapies for asthma within 3 months of screening
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedPharmacokinetics of PRA-216: T1/2Tmax in patients with COPDTime frame: 40 weeks
    • DescriptionThe effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in COPD participants: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07730281
Lead sponsor
Prana Therapies Inc
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Aug 25, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion